KR101928418B1 - 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제 - Google Patents

잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제 Download PDF

Info

Publication number
KR101928418B1
KR101928418B1 KR1020157000512A KR20157000512A KR101928418B1 KR 101928418 B1 KR101928418 B1 KR 101928418B1 KR 1020157000512 A KR1020157000512 A KR 1020157000512A KR 20157000512 A KR20157000512 A KR 20157000512A KR 101928418 B1 KR101928418 B1 KR 101928418B1
Authority
KR
South Korea
Prior art keywords
mod
res
phosphorothioate
nucleic acid
locked nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157000512A
Other languages
English (en)
Korean (ko)
Other versions
KR20150023687A (ko
Inventor
루이 에바 반
크리스티나 엠 돌비
러스티 엘 몽고메리
Original Assignee
미라젠 세러퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미라젠 세러퓨틱스 인코포레이티드 filed Critical 미라젠 세러퓨틱스 인코포레이티드
Publication of KR20150023687A publication Critical patent/KR20150023687A/ko
Application granted granted Critical
Publication of KR101928418B1 publication Critical patent/KR101928418B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020157000512A 2012-06-21 2013-06-21 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제 Expired - Fee Related KR101928418B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662746P 2012-06-21 2012-06-21
US61/662,746 2012-06-21
US201361801533P 2013-03-15 2013-03-15
US61/801,533 2013-03-15
PCT/US2013/047157 WO2013192576A2 (en) 2012-06-21 2013-06-21 Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Publications (2)

Publication Number Publication Date
KR20150023687A KR20150023687A (ko) 2015-03-05
KR101928418B1 true KR101928418B1 (ko) 2018-12-12

Family

ID=49769732

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000512A Expired - Fee Related KR101928418B1 (ko) 2012-06-21 2013-06-21 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제

Country Status (12)

Country Link
US (3) US9388408B2 (enExample)
EP (2) EP2864482A4 (enExample)
JP (2) JP6208228B2 (enExample)
KR (1) KR101928418B1 (enExample)
CN (2) CN104685056A (enExample)
AU (1) AU2013278011B2 (enExample)
CA (1) CA2876180C (enExample)
DK (1) DK3354734T3 (enExample)
ES (1) ES2801875T3 (enExample)
HK (2) HK1209781A1 (enExample)
MX (1) MX355408B (enExample)
WO (1) WO2013192576A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083005A2 (en) * 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
CN103620035B (zh) 2011-04-25 2021-04-23 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
BR112014026639A8 (pt) 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP2757157A1 (en) * 2013-01-17 2014-07-23 Ecole Polytechnique Federale de Lausanne (EPFL) Modulation of mitophagy and use thereof
CN105188715B (zh) 2013-03-15 2018-12-25 米拉根医疗股份有限公司 Mir-145的锁定核酸抑制剂及其用途
NZ630890A (en) 2013-05-01 2017-09-29 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
AR101449A1 (es) * 2014-08-04 2016-12-21 Miragen Therapeutics Inc Inhibidores de myh7b y usos de los mismos
JP2017523790A (ja) 2014-08-07 2017-08-24 レグルス セラピューティクス インコーポレイテッド 代謝障害のためのマイクロｒｎａの標的化
WO2016069717A1 (en) * 2014-10-28 2016-05-06 MiRagen Therapeutics, Inc. Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
SG11201705907XA (en) * 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
US10538769B2 (en) 2015-09-04 2020-01-21 Oregon State University Renal selective inhibition of cytochrome P450 3A5
CA2997786A1 (en) * 2015-09-22 2017-03-30 MiRagen Therapeutics, Inc. Mir-19 modulators and uses thereof
EP3985116A1 (en) * 2015-10-15 2022-04-20 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
CN105435247A (zh) * 2015-12-31 2016-03-30 中国医学科学院基础医学研究所 miR-378在预防和/或治疗肥胖症中的用途
EP3449001B1 (en) 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN106011140B (zh) * 2016-06-06 2018-12-18 同济大学 反义microRNA-25及其应用
WO2017214953A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用
WO2017214952A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用
WO2017219166A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 一种同时抑制双 miRNA 表达的慢病毒载体及其应用
WO2017219165A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
EP3481404A4 (en) * 2016-07-07 2020-03-25 Miragen Therapeutics, Inc. METHODS OF TREATING SKIN T LYMPHOMA (CT) WITH MIR-155 INHIBITORS
CN109891245B (zh) 2016-08-12 2023-05-05 美国创新免疫科技有限公司 自身免疫疾病的诊断、预防和/或治疗
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018183127A1 (en) * 2017-03-25 2018-10-04 MiRagen Therapeutics, Inc. Mir-92 inhibitors for treatment of heart failure
CN110141577A (zh) * 2018-02-13 2019-08-20 上海三炬生物科技有限公司 miRNA-24-3p核苷酸类似物在制备药物中的应用
JP7318166B2 (ja) * 2018-03-14 2023-08-01 ベス イスラエル デアコネス メディカル センター マイクロｒｎａ２２の阻害剤
WO2019217369A1 (en) 2018-05-08 2019-11-14 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
US20220056443A1 (en) * 2018-09-06 2022-02-24 Aptamir Therapeutics, Inc. Metabolic benefits of short mir-22 mirna antagomir therapies
CN110358769A (zh) * 2019-07-30 2019-10-22 中国医学科学院血液病医院(中国医学科学院血液学研究所) 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用
CN110433170B (zh) * 2019-07-31 2021-04-27 南京医科大学 心脏抽吸液miR-28-5p在心脏疾病中的应用
IT201900017234A1 (it) * 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
US20220395587A1 (en) * 2019-11-15 2022-12-15 Duke University Cellular molecular theranostics nanoprobe systems and methods
CN111118008B (zh) * 2020-01-16 2023-08-22 南京医科大学 Mcl1基因的3’-UTR序列及其应用
WO2021178344A1 (en) * 2020-03-04 2021-09-10 The Trustees Of Indiana University Methods to re-engage a fetal wound healing pathway for adult skin repair
EP4185694A1 (en) * 2020-07-23 2023-05-31 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN116801916A (zh) * 2021-01-18 2023-09-22 礼赞伊诺制药株式会社 包含miR 145抑制剂作为有效成分的用于治疗心肌梗塞的组合物
CN120584186A (zh) 2023-02-07 2025-09-02 特罗姆瑟大学-挪威北极圈大学 用于在静脉血栓栓塞的治疗中使用的药物组合物
GB202305535D0 (en) 2023-04-14 2023-05-31 Imperial College Innovations Ltd Oligonucleotide decoy
WO2025008641A2 (en) * 2023-07-06 2025-01-09 Imperial College Innovations Limited Rna molecule
WO2025104709A1 (en) * 2023-11-17 2025-05-22 Biorchestra Co., Ltd. Microrna-378a-3p antisense oligonucleotides and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061810A1 (en) * 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
AU7404994A (en) 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
EP1082012A4 (en) 1998-05-26 2002-01-16 Icn Pharmaceuticals NEW NUCLEOSIDES WITH BICYCLICAL SUGAR PART
NZ514104A (en) 1999-03-18 2001-09-28 Exiqon As Detection of mutations in genes by specific LNA primers
AU7406600A (en) 1999-10-04 2001-05-10 Exiqon A/S A method of increasing the specificity of oxy-lna oligonucleotides
JP4413493B2 (ja) 2000-10-04 2010-02-10 サンタリス ファーマ アー／エス プリンｌｎａ類似体の改善された合成方法
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
EP1549352A4 (en) 2002-05-06 2005-07-27 Nucleonics Inc METHOD OF DISTRIBUTING NUCLEIC ACIDS
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
CA2506576C (en) 2002-11-18 2018-03-06 Santaris Pharma A/S Antisense gapmer oligonucleotides
EP1606406B2 (en) * 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
US8685946B2 (en) 2003-11-26 2014-04-01 Universiy of Massachusetts Sequence-specific inhibition of small RNA function
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
CA2556435C (en) 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
JP4819788B2 (ja) 2004-02-26 2011-11-24 オスプレイ メディカル インク． 分離用心循環
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
EP2290070B1 (en) 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
ES2534302T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US9550990B2 (en) 2004-12-10 2017-01-24 Ionis Pharmaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
CN101203611B (zh) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 控制基因表达的改良方法
HUE027013T2 (en) 2005-05-27 2016-10-28 Ospedale San Raffaele Srl A gene vector containing MI-RNA
NZ569738A (en) 2005-12-12 2012-03-30 Univ North Carolina MicroRNAs (miRNA) that regulate muscle cell proliferation and differentiation
US20100286044A1 (en) 2005-12-29 2010-11-11 Exiqon A/S Detection of tissue origin of cancer
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2008014008A2 (en) 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
MX2009001281A (es) 2006-08-01 2009-04-16 Univ Texas Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina.
US20090306181A1 (en) 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
EP2476762B1 (de) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
US20100021914A1 (en) 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
CN102604951A (zh) 2006-12-14 2012-07-25 诺瓦提斯公司 治疗肌肉和心血管病症的组合物和方法
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US20090105174A1 (en) 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
CA2694928A1 (en) 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
US20100292099A1 (en) 2007-08-23 2010-11-18 Keren Pharmaceutical, Inc. Targeting of rna with external guide sequences
EP2610342B1 (en) 2007-09-14 2016-05-04 The Ohio State University Research Foundation MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof
KR101889518B1 (ko) 2007-10-04 2018-08-17 로슈 이노베이션 센터 코펜하겐 에이/에스 마이크로ＭＩＲｓ
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
CN101424640B (zh) 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
CN101951924B (zh) 2007-11-09 2015-06-24 得克萨斯系统大学董事会 Mir-15家族的微小rna调控心肌细胞存活和心脏修复
WO2009088786A1 (en) 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. Rna interference for the treatment of heart failure
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US20110160285A1 (en) 2008-03-13 2011-06-30 The Regents Of The University Of Colorado Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
AU2009256243A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
US20110152352A1 (en) 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
WO2010000665A1 (en) * 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
CN101386848A (zh) 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2358398A2 (en) 2008-10-24 2011-08-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5943608B2 (ja) 2009-02-04 2016-07-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心臓障害の治療におけるｍｉｒ−２０８およびｍｉｒ−４９９の二重ターゲティング
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
WO2010129672A1 (en) 2009-05-05 2010-11-11 Miragen Therapeutics Lipophilic polynucleotide conjugates
CN102803284B (zh) 2009-06-08 2015-11-25 米拉根医疗公司 用于miRNA抑制剂和模拟物的化学修饰基序
EP2475372B2 (en) 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
US8592151B2 (en) 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
WO2011106442A1 (en) 2010-02-24 2011-09-01 The Board Of Trustees Of The Leland Stanford Junior University Control of cardiac growth, differentiation and hypertrophy
US20130079505A1 (en) 2010-03-24 2013-03-28 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
EP2559442B1 (en) 2010-04-13 2017-12-06 Jiangsu Mingma Biotech Co., Ltd Method for regulating microrna content in organisms and uses thereof
WO2011131354A1 (en) 2010-04-20 2011-10-27 Febit Holding Gmbh Complex mirna sets as novel biomarkers for an acute coronary syndrome
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
ITMI20101089A1 (it) 2010-06-16 2011-12-17 Istituto Naz Di Genetica Molecolare Ingm Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
WO2012006577A2 (en) 2010-07-08 2012-01-12 Duke University Direct reprogramming of cells to cardiac myocyte fate
GB201012418D0 (en) * 2010-07-23 2010-09-08 Santaris Pharma As Process
WO2012018866A2 (en) 2010-08-03 2012-02-09 University Of South Alabama Methods and compositions for the diagnosis and treatment of breast cancer
WO2012020307A2 (en) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
EP2609198B8 (en) 2010-08-24 2018-03-28 Sirna Therapeutics, Inc. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
JP2013541334A (ja) 2010-09-15 2013-11-14 アルニラム ファーマスーティカルズ インコーポレイテッド 修飾されたｉＲＮＡ剤
WO2012083005A2 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
WO2012149646A1 (en) 2011-05-05 2012-11-08 Sunnybrook Research Institute Mirna inhibitors and their uses
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
GB201117482D0 (en) 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
EP2768958B1 (en) 2011-10-18 2019-08-14 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
EP2604690A1 (en) 2011-12-15 2013-06-19 Oncostamen S.r.l. MicroRNAs and uses thereof
WO2013088338A1 (en) 2011-12-15 2013-06-20 Oncostamen S.R.L. Micrornas and uses therof
FR2984358A1 (fr) 2011-12-16 2013-06-21 Genethon Methodes pour le diagnostic de dystrophies musculaires
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
PL2759595T3 (pl) 2013-01-24 2017-09-29 Pierre Fabre Médicament S.A.S. Kompozycja zawierająca kapsułkowany antagomir
SG11201705907XA (en) 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061810A1 (en) * 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides

Also Published As

Publication number Publication date
US9803202B2 (en) 2017-10-31
US20160326526A1 (en) 2016-11-10
MX355408B (es) 2018-04-18
CN104685056A (zh) 2015-06-03
JP2015521626A (ja) 2015-07-30
HK1209781A1 (en) 2016-04-08
US10337005B2 (en) 2019-07-02
JP2017217007A (ja) 2017-12-14
EP3354734A1 (en) 2018-08-01
ES2801875T3 (es) 2021-01-14
WO2013192576A2 (en) 2013-12-27
KR20150023687A (ko) 2015-03-05
WO2013192576A3 (en) 2014-04-03
EP3354734B1 (en) 2020-06-10
AU2013278011B2 (en) 2018-09-20
US20130344135A1 (en) 2013-12-26
EP2864482A2 (en) 2015-04-29
AU2013278011A1 (en) 2015-01-15
JP6208228B2 (ja) 2017-10-04
EP2864482A4 (en) 2016-02-10
DK3354734T3 (da) 2020-06-29
MX2014015643A (es) 2015-07-17
CA2876180C (en) 2019-11-19
CN107236735A (zh) 2017-10-10
US20180273944A1 (en) 2018-09-27
US9388408B2 (en) 2016-07-12
HK1244509A1 (zh) 2018-08-10
CN107236735B (zh) 2019-11-08
CA2876180A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
KR101928418B1 (ko) 잠금 핵산 모티프를 포함하는 올리고뉴클레오티드-기반 억제제
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
KR20150036140A (ko) 마이크로RNAs의 MIR-15 패밀리의 억제제
KR20140004646A (ko) 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
HK1259394A1 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211207